Expression and significance of histone H3K27 demethylases in renal cell carcinoma by Yongqing Shen et al.
Shen et al. BMC Cancer 2012, 12:470
http://www.biomedcentral.com/1471-2407/12/470RESEARCH ARTICLE Open AccessExpression and significance of histone H3K27
demethylases in renal cell carcinoma
Yongqing Shen1,5†, Xiaoqiang Guo1,2†, Yuejia Wang1, Wei Qiu4, Yanzhong Chang1, Aili Zhang3*
and Xianglin Duan1*Abstract
Background: The histone H3K27 demethylases UTX and JMJD3 are important regulatory factors that modulate
gene expression by altering the physical state of chromatin. Previous studies have indicated an abnormal H3K27
methylation status in carcinogenesis. We therefore investigated the expression patterns of UTX and JMJD3 in renal
cell carcinoma (RCC) and their roles in cancer development.
Methods: The mRNA expression levels of the UTX and JMJD3 genes were determined in cancer tissues and
adjacent normal tissues in 36 patients with primary RCC, using quantitative real-time-polymerase chain reaction.
The UTX and JMJD3 protein contents were measured by western blotting and immunohistochemical analysis.
Results: UTX and JMJD3 transcripts were significantly increased in cancer tissues compared to normal tissues
(P < 0.05). mRNA levels of the inhibitor of cyclin-dependent kinases 4 and 6 p16INK4a were also increased in cancer
tissues (P < 0.001). Western blotting indicated that levels of both demethylases were increased in cancer tissues. The
level of tri-methylated H3K27 (H3K27me3) was lower in cancer tissues compared to normal tissues, but expression
of the H3K27 methyltransferase EZH2 was increased (P < 0.05). These results suggest that the two H3K27
demethylases may play critical roles in the regulation of H3K27 methylation status in RCC. Immunohistochemical
analysis confirmed that UTX and JMJD3 expression were upregulated in cancer tissues compared to adjacent
tissues.
Conclusions: This study demonstrated that UTX and JMJD3 were upregulated in cancer tissues, suggesting that
they may be involved in the development of primary RCC. The potential roles of H3K27 demethylases as
biomarkers in the early diagnosis of RCC need to be further explored.
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Background radiation therapy [4,5]. Radical or partial nephrectomy
Kidney cancer is the third most common urological ma-
lignancy and is responsible for an estimated 120,000
deaths per year worldwide [1]. The incidence of kidney
cancer has increased significantly over the past 20 years
[2], and accounts for nearly 3% of all cancer cases in
Europe [3]. The two most common types of kidney can-
cer are renal cell carcinoma (RCC) and urothelial cell
carcinoma. RCC is the most common kidney cancer in
adults, and is generally resistant to chemotherapy and* Correspondence: xlduan0311@163.com; Zhangaili1967@hotmail.com
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reproduction in any medium, provided the orof the tumor at a localized stage remains the mainstay of
curative therapy [6]. Unfortunately, however, distant me-
tastases are present at the time of initial diagnosis in ap-
proximately one third of patients, and the tumor will
recur in a further third, even after nephrectomy with
curative intent [7,8]. In addition, there is lack of specific
diagnostic markers for RCC, which is an important con-
tributory factor in its poor prognosis [9]. A better under-
standing of the molecular basis of RCC has facilitated
the development of novel and more selective diagnostic
and therapeutic approaches.
Many studies have shown that epigenetic modification
plays an important role in cancer development [10]. His-
tone methylation is essentially a post-translational and epi-
genetic modification, which is miswritten, misinterpretedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographics of patients and tumor
characteristics of radical nephrectomy specimens
Characteristics Number








Tumor size (cm) Mean 4.2
Range 1.1~10.5








Lymph node Negative 63
Positive 0
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RCC [11]. Histone methylation can occur at certain
amino acids including lysine (K) and arginine (R) in the
N-terminus of histones H3 and H4, by the addition of one,
two, or three methyl groups. H3K27 methylation is a re-
versible process that can be catalyzed by histone lysine
methyltransferase 6 (KMT6, also known as EZH2), and the
demethylases 6A (KDM6A, also known as ubiquitously-
transcribed TPR gene on the X chromosome, UTX) and 6B
(KDM6B, also known as jumonji domain-containing pro-
tein 3, JMJD3) [12]. Tri-methylated histone H3K27
(H3K27me3) is a suppressor marker that inhibits the ex-
pression of specific target genes by altering the physical
state of chromatin. EZH2 (enhancer of zeste homolog 2)
can be regarded as an oncogene and is frequently overex-
pressed in a wide variety of cancers [13], including RCC
[14,15]. Several studies have identified UTX and JMJD3 as
H3K27-specific demethylases that contribute to gene acti-
vation [16-20]. Both UTX and JMJD3 are considered as
tumor suppressors, and inactivating somatic mutations of
UTX are frequently observed in several tumor types, in-
cluding RCC [21]. However, the relationship between
the expression of these two enzymes and cancer de-
velopment is largely unknown. In this study, we
therefore investigated the gene and protein expression
levels of UTX and JMJD3 and their clinical signifi-
cance in RCC.
Methods
Patients and tissue specimens
Sixty-three patients were diagnosed with clear cell RCC
by computed tomography (CT) combined with clinical
symptoms, and the diagnoses were confirmed by clinico-
pathological examination at the Fourth Clinical Medical
College of Hebei Medical University (Shijiazhuang,
China). All cancer tissues and paired adjacent tissues
were obtained through radical nephrectomy. Written
informed consent was obtained from all patients before
surgery and the study was approved by the Human
Research Ethics Committee of The Fourth Clinical
Medical College of Hebei Medical University. Histo-
logical classification (Additional file 1: Figure S1)
was performed according to the standard provided by
Fuhrman et al. [22] and postoperative pathological
staging was performed in all cases (Table 1).
Quantitative real-time-polymerase chain reaction
(qRT-PCR)
Total RNA was extracted from cancer tissues and adjacent
tissues with Trizol reagent (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s protocol. The total
RNA concentration was determined using a NanoDrop
ND-1000 spectrophotometer (Thermo Scientific, Wil-
mington, DE, USA). cDNA was synthesized from 2 μg oftotal RNA using a RT system, according to the manufac-
turer’s instructions (Invitrogen). The mRNA expression
levels of UTX, JMJD3, EZH2 and p16INK4a were analyzed
using SYBR green PCR Mix (Tiangen, Beijing, China),
with 18S rRNA as an internal reference. qRT-PCR was
performed using a 7500 RealTime PCR System (Applied
Biosystems, Foster City, CA, USA). Primer sequences were
synthesized by Sangon (Shanghai, China) and included:
UTX forward 5’- TTTGTCAATTAGGTCACTTCAAC
CTC −3’ and UTX reverse 5’- AAAAAGGCAGCATTCTT
CCAGTAGTC −3’, JMJD3 forward 5’- GGAGGCCACAC
GCTGCTAC −3’ and JMJD3 reverse 5’- GCCAGTATGA
AAGTTCCAGAGCTG-3’, EZH2 (isoforms 1–5) forward
5’- GGGACAGTAAAAATGTGTCCTGC-3’ and EZH2
reverse 5’-TGCCAGCAATAGATGCTTTTTG-3’, INK4A
(isoforms 1/2) forward 5’- GAAGGTCCCTCAGACATCC
CC −3’ and INK4A reverse 5’- CCCTGTAGGACCTTCG
GTGAC −3’, 18S rRNA forward 5’-CGGCGGCTTT GGT
GACTCTAG-3’ and 18S rRNA reverse 5’-CCGTTTCTC
AGGCTCCCTCTCC-3’. Relative expression levels of
the four genes were normalized to the internal refe-
rence 18S RNA. Data were analyzed using the com-
parative threshold cycle (2-ΔCT) method.
Western blotting
Cancer tissues and adjacent normal tissues from all 63
patients were homogenized in radioimmunoprecipita-
tion assay buffer containing the protease inhibitors
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(1 mmol/L) and dithiothreitol (0.5 mmol/L). Homoge-
nates were centrifuged and supernatants were collected.
Protein concentrations were determined using a Nano-
Drop ND-1000 and corrected appropriately. A total of
50 μg of protein from each sample was resolved by re-
ducing loading buffer and separated by 8% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis fol-
lowed by electrophoretic transfer to a nitrocellulose
(NC) membrane. The NC membrane was saturated with
5% skim milk in TBST (50 mM Tris–HCl, 150 mM
NaCl, 0.1% Tween-20) for 2 h and then incubated with
primary antibodies at 4°C overnight. The primary anti-
bodies used included rabbit polyclonal antibodies to
UTX (1:1,000, Abcam, Hong Kong, China), JMJD3
(1:1500, Abcam), EZH2 (1:500, Santa Cruz Biotechnol-
ogy, Hong Kong, China), H3K27me3 (1:1,500, Epigen-
tek, Brooklyn, USA), H3 (1:2,000, Sigma-Aldrich,
St Louis, USA) and actin (1:2,500, Sigma, St Louis,
USA). NC membranes were incubated with 1:5,000-
diluted peroxidase-coupled goat anti-rabbit immuno-
globulin G (IgG) (secondary antibody, Sigma) for 1 h,
after washing three times with TBST (5 min/time) at
room temperature. After further washing with TBST
four times, the NC membranes were exposed to
enhanced chemiluminescence substrate (Pierce, Rock-
ford, USA) for 5 min and detection was performed using
a Fujifilm LAS-4000 imaging system (GE Healthcare,
Bucks, UK).
Immunohistochemical analysis
After fixation in 4% formalin, cancer tissues and adjacent
normal tissues from the 63 RCC patients were dehy-
drated through an ascending series of graded ethanols,
embedded in paraffin wax, and cut into 5-μm sections
using a microtome. The endogenous peroxidase activity
of sections was inhibited by treatment with 3% H2O2/
methanol. Antigen retrieval was performed on xylene-
deparaffinized and dehydrated sections by heating the
slides for 10 min in 0.01 M citrate buffer (pH 6.0). Non-
specific binding was blocked by incubating sections with
5% BSA in a humidified chamber. Sections were then
incubated overnight at 4°C with 1:100 dilution of anti-
UTX or anti-JMJD3 primary polyclonal rabbit antibodies
(Abcam). After washing twice in PBS, sections were trea-
ted with peroxidase-conjugated AffiniPure goat anti-
rabbit IgG (ZSGB Bio, Beijing, China) at room
temperature for 30 min, followed by diaminobenzidine
(ZSGB Bio) as a chromogen to visualize the peroxidase
activity. A negative immunohistochemical control was
provided by replacement of the primary antibodies by
antibody diluents.
The protein expression scores for both UTX and
JMJD3 were quantitated according to Wu et al. [23].Briefly, the proportions of UTX/JMJD3-expressing
tumor cells were scored as follows: 0, no positive cells; 1,
<5%; 2, 6–25%; 3, 26–50%; 4, 51–75%; and 5, >75%.
Staining intensity was graded according to the mean op-
tical density: 0, no staining; 1, weak staining (light yel-
low); 2, moderate staining (yellow-brown); and 3, strong
staining (brown). The staining index was calculated as
the product of the staining intensity score and the pro-
portion of UTX/JMJD3-positive tumor cells.
Statistical analysis
Statistical analysis was carried out using the SPSS 17.0
statistical software package. qRT-PCR and immunohisto-
chemical data were analyzed by two-tailed paired-sample
t-tests and Mann–Whitney U tests (α = 0.05). A P value
of ≤ 0.05 was considered to indicate a statistically signifi-




A total of 63 samples of cancer tissues and paired adja-
cent normal tissues were available from patients with
RCC who had undergone surgery. All the patients were
treated by radical nephrectomy and received no pre-
operative radiation or chemotherapy y. Most patients
(56/63) were at an early stage (stages 1 and 2), and no
lymph node metastasis was present in any patients. The
overall 5-year survival rate was 100%, suggesting that
early diagnosis and surgical removal of the cancer tissue
resulted in a good prognosis. The clinical data are shown
in Table 1.
mRNA expression levels of UTX and JMJD3 in cancer
tissues and adjacent normal tissues in RCC patients
The transcription levels of the two H3K27 demethylase
genes, UTX and JMJD3, the H3K27 methyltransferase
EZH2 and the CDK4/CDK6 inhibitor p16INK4a were
determined by qRT-PCR in cancer tissues and adjacent
normal tissues from 36 RCC patients. The mRNA levels
of UTX, JMJD3 and EZH2 were significantly increased in
cancer tissues compared to the adjacent tissues (P < 0.05,
Figure 1), while the expression of p16INK4a mRNA
was highly significantly upregulated in cancer tissues
(P < 0.001, Figure 1).
Levels of UTX and JMJD3 proteins in cancer tissues and
adjacent normal tissues in RCC patients
To support the changes in mRNA levels of UTX and
JMJD3, the protein contents of the two H3K27 demethy-
lases were measured by western blotting. Levels of UTX
and JMJD3 proteins were obviously increased in cancer
tissues compared to adjacent normal tissues (Figure 2),
Figure 1 Real-time qRT-PCR analysis of the H3K27
demethylases UTX and JMJD3, the H3K27 methyltransferase
EZH2 and the CDK4/CDK6 inhibitor p16INK4a. Relative mRNA
expression levels of UTX, JMJD3 and EZH2 were higher in RCC cancer
tissues than in paired adjacent normal tissues (n = 36; all P < 0.05).
The mRNA level of p16INK4a was also upregulated in cancer tissues
compared to adjacent normal tissues (P < 0.001).
Figure 3 Changes in UTX and JMJD3 protein expression levels
in RCC. Levels of UTX and JMJD3 proteins were higher in RCC
cancer tissue samples (C) than in paired adjacent normal tissue
samples (A) (n = 63, P < 0.05).
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methyltransferase EZH2 was upregulated (Figure 2).
Changes in UTX and JMJD3 expression in cancer tissues
and adjacent normal tissues in RCC patients analyzed by
immunohistochemistry
The expression and subcellular localization of the two
H3K27 demethylases UTX and JMJD3 were further
determined by immunohistochemical analysis in 63
paraffin-embedded RCC cancer tissues and paired adja-
cent tissues. The H3K27 demethylases were localized
mainly in the nucleus in renal tissue. UTX and JMJD3Figure 2 Western blotting analysis of H3K27 methylation-
modifying enzymes and H3K27me3 levels. The protein
expression levels of the H3K27 demethylases UTX and JMJD3 were
higher in RCC cancer tissues (C) than in paired adjacent normal
tissues (A). The H3K27me3 level was lower in RCC cancer tissues,
although the protein level of the H3K27 methyltransferase EZH2
was increased.protein contents were higher in cancer tissues than in
adjacent normal tissues (P < 0.01, Figures 3, 4, and 5).
Discussion
Histone demethylases are known to be closely related to
tumor formation [24] and several studies have also indi-
cated an association between the H3K9 demethylase
JMJD1A and RCC [25,26]. The role of histone demethy-
lases in RCC is thus worthy of further investigation.
Both UTX and JMJD3 are H3K27me3 demethylases and
are essential for the expression of many genes, including
HOX, through decreasing the levels of H3K27me3
[16,17]. Inactivating somatic mutations of UTX and
reduced expression of JMJD3 have been demonstrated in
many cancers [21,27]. Both UTX and JMJD3 can be con-
sidered as candidate tumor suppressors [28,29], and may
be involved in tumor suppression via an oncogene-
induced senescence (OIS) mechanism.
The human tumor suppressor genes INK4b-ARF-
INK4a are located on chromosome 9p21 and encode the
proteins p16INK4a, p15INK4b and p14ARF. p16INK4a/
p15INK4b are CDK4/CDK6 inhibitors and block retino-
blastoma protein (Rb) phosphorylation and inactivation,
which enhances the pRB-E2F signaling pathway. p14ARF
inhibits the activity of p53-specific ubiquitin ligase mur-
ine double minute 2 (MDM2), which increases expres-
sion of p53 protein [30]. These three proteins are
involved in senescence regulation and induction of cell
cycle arrest at the G0/G1 phase, leading to cell senes-
cence [31]. Cellular senescence causes irreversible
growth arrest, while OIS is an important preventive
mechanism for pre-cancerous damage [32] and can ef-
fectively block uncontrolled cell proliferation induced by
Figure 4 Immunohistochemical analysis of UTX expression. UTX protein expression was obviously higher in cancer tissues (C and D) than in
adjacent normal tissues (A and B). Magnifications × 200 (A and C) and × 400 (B and D).
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can lead to unlimited cell proliferation and eventually to
cancer development [33].
The INK4b-ARF-INK4a locus is regulated by many
factors, including histone modification [34]. The poly-
comb repressive complex 2 (PRC2) containing EZH2
can bind the INK4b-ARF-INK4a locus and silence their
gene expressions through increasing local H3K27me3
content, which in turn promotes cell proliferation and
reduces cell senescence [35,36]. In contrast, JMJD3Figure 5 Immunohistochemical analysis of JMJD3 expression. JMJD3 p
than in adjacent normal tissues (A and B). Magnifications × 200 (A and C) abinding to the INK4b-ARF-INK4a locus can inhibit
PRC2 occupancy and decrease H3K27me3 content,
resulting in the increased expressions of these three pro-
teins and promotion of cell senescence [29]. In primary
Hodgkin’s lymphoma, JMJD3 is over-expressed and
induced by the Epstein-Barr virus oncogene [37]. The
results of our study revealed that H3K27me3 levels were
lower in cancer tissues compared to adjacent normal tis-
sues, accompanied by increased JMJD3 expression. Con-
sistent with the strong decrease in H3K27me3 levels,rotein expression was obviously higher in cancer tissues (C and D)
nd × 400 (B and D).
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cer tissues compared to normal tissues. Previous re-
search indicated that homozygous deletions of the
INK4a/ARF locus contributed to tumor progression in
RCC [38]. These results suggest that inactivation or
down-regulation of p16INK4a is a later event in RCC
progression.
UTX also plays an important role in cell senescence in
tumor suppression. The tumor suppressor Rb and its
binding proteins are regulated by UTX-catalyzed
H3K27me3 demethylation [39]. UTX can occupy the
promoter region of Rb and the related gene Rbl2 (retino-
blastoma-like protein 2) and increase their expression,
thus reducing cell proliferation and increasing cell senes-
cence [40]. In Drosophila, UTX-mutant cells showed
tumor-like growth characteristics accompanied by
reduced Rb expression [41]. In the current study, UTX
expression was obviously higher in cancerous tissues at
both the mRNA and protein levels. Although all three of
these proteins are upregulated in RCC, the reduction in
H3K27me3 level implies that the H3K27 demethylases
UTX and JMJD3 play more important roles than the
H3K27 methyltransferase EZH2 in regulating p16INK4a
expression.
Previous studies demonstrated that abnormal H3K27
levels or EZH2 expression were associated with cancer
development and prognosis [14,42]. This study also
demonstrated that upregulated expression of the H3K27
demethylases UTX and JMJD3 was relevant to tumor
suppression. Previous studies found evidence for JMJD3
regulation in tissues from many cancers, including pros-
tate cancer and primary Hodgkin’s lymphoma [20,37].
Further studies of the relationship between histone
demethylases and cancer development will improve our
understanding of the molecular mechanisms involved,
and potentially aid in the development of new therapies
for RCC [43,44]. The possible roles of UTX and JMJD3
in RCC can be summarized as follows: oncogene activa-
tion leads to increased binding of JMJD3 to the
p16INK4a promoter and subsequent transcriptional in-
duction through demethylation of H3K27me3 at the
INK4A-ARF locus [31]. p16INK4a then inhibits RCC de-
velopment via induction of cell cycle arrest. However,
our understanding of the mechanism underlying cell
senescence in tumor suppression is currently limited,
and further studies are needed to clarify the roles of
UTX and JMJD3 in RCC.
Conclusions
In summary, this study revealed that upregulated expres-
sion levels of UTX and JMJD3 are common in cancer tis-
sues in early stage RCC patients with a good prognosis.
These H3K27 demethylases may inhibit cell proliferation
in primary RCC through OIS. The results also imply thatidentification of the genes regulated by UTX and JMJD3
during RCC development will improve our understanding
of the carcinogenesis and screening strategies in RCC.
The potential roles of H3K27 demethylases as biomarker
(s) for the early diagnosis of RCC and for prognostic
evaluation need to be investigated.
Additional file
Additional file 1: Figure S1. The pathological stage of RCC. The A~D
represents grade 1~4 of RCC according to the standard presented by
Fuhrman et al [22].
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